Latest Deals

Credit: 

Teleflex signed a definitive agreement to take over Palette Life Sciences for an upfront cash deal of $600m. Palette will also receive an additional $50m from Teleflex based on certain commercial milestone achievements. 

With the addition of non-animal stabilised hyaluronic acid (NASHA) spacer and tissue bulking products, the acquisition will broaden the Teleflex Interventional Urology portfolio. The new additions via the acquisition will help enhance patient outcomes in urology and urogynecology disorders, colorectal conditions and radiation oncology procedures. 

Proprio secured $43m in a Series B financing round conducted by existing and new investors. In April this year, the FDA cleared the Seattle, US-based company’s lead product Paradigm. The platform combines light-field technology with artificial intelligence (AI) to provide a real-time 3D surgical navigation platform.

Laplace Interventional, a US based medical device company developing transcatheter tricuspid valve technology, closed a $12.9 million Series B financing round. The financing, which was co-led by ShangBay Capital and Features Capital, with additional participation from Engage Venture Partners, and JWC Ventures, will be used to excel Laplace Interventional strategy for its First-in-Human (FIH) trials of its transcatheter valve system.

China-based Atantares has raised approximately 100m yuan ($13.9m) in a pre-Series A and pre-Series A+ financing round. The proceeds are expected to finance research and development, service operation, and capacity expansion.